Protocols to demonstrate slowing of Alzheimer Disease progression: Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines

Alzheimer Disease and Associated Disorders

Volumn 11, Issue SUPPL. 3, 1997, Pages 50-53

  Bodick, Neil ^a   Forette, Françoise ^b   Hadler, Dietrich ^c   Harvey, Richard J ^d   Leber, Paul ^e   McKeith, Ian G ^f   Riekkinen, Paavo J ^g   Rossor, Martin N ^d   Scheltens, Philip ^h   Shimohama, Shun ⁱ   Spiegel, Rene ^j   Tanaka, Satoru ^k   Thal, Leon J ^l   Urata, Yasuo ^m   Whitehouse, Peter ⁿ   Wilcock, Gordon ^o  

^a ELI LILLY AND COMPANY   (United States)

^b Paris Descartes University   (France)

^c Takeda Pharma GmbH   (Germany)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^g UNIVERSITY OF EASTERN FINLAND   (Finland)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ KYOTO UNIVERSITY   (Japan)

^j Sandoz Pharma Ltd   (Switzerland)

^k DAIICHI SANKYO CO   (Japan)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m JAPAN TOBACCO INC   (Japan)

ⁿ UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^o UNIVERSITY OF BRISTOL   (United Kingdom)

more..

Author keywords

Alzheimer disease progression; Clinical trials; Experimental design

Indexed keywords

NOOTROPIC AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; GERIATRIC ASSESSMENT; HUMAN; INTERNATIONAL COOPERATION; MALE; MEDICAL ETHICS; PRACTICE GUIDELINE; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

AGED; ALZHEIMER DISEASE; ETHICS, MEDICAL; FEMALE; GERIATRIC ASSESSMENT; HUMANS; INTERNATIONAL COOPERATION; MALE; NOOTROPIC AGENTS; PRACTICE GUIDELINES; PSYCHOMETRICS; RANDOMIZED CONTROLLED TRIALS;

EID: 0030626839     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (5)

1. Jobst KA, Smith AD, Szatmari M, et al. Rapidly progressing atrophy of medial temporal lobe in Alzheimer's disease. Lancet 1994;343: 829-30.
2. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease: the Tacrine Study Group. JAMA 1994;271:985-91.
3. Knopman DS, Knapp MJ, Gracon SI, Davis CS. The clinician interview-based impression (CIBI) - a clinician global change rating-scale in Alzheimer's-disease. Neurology 1994;44:2315-21.
4. Leber P. Observations and suggestions on antidementia drug development. Alzheimer Dis Assoc Disord 1996;10(Suppl 1):31-5.
5. Rosen WG, Mohs RC, Davis K. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.